Skip to main content
Premium Trial:

Request an Annual Quote

ImmunID, Singapore Immunology Network Collaborate on Immune Study

NEW YORK (GenomeWeb) – French immune molecular diagnostics firm ImmunID on Tuesday announced a deal with the Singapore Immunology Network (SigN) for research into immune competence.

Under the terms of the agreement, ImmunID will use its ImmunTracker and ImmunIG tests to evaluate T and B immune repertoire diversity in the blood of patients enrolled in a SigN-led clinical trial. The indication and therapeutic intervention being studied in the trial were not disclosed.

SigN is a research institute under Singapore's Agency of Science, Technology, and Research.

Anis Larbi, the principal investigator for the trial, said that ImmunID's technology broadens SigN's research efforts into the human immune system. "We can now get a more comprehensive understanding of it, using parameters such as immune repertoire diversity, which were neglected in the past," he said in a statement.

The project is for two years and will include 180 patients.